1-(2,3,3-Trimethylbutan-2-yl)-1,2,4-triazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(2,3,3-Trimethylbutan-2-yl)-1,2,4-triazole
• 英文别名: 1-(2,3,3-trimethylbutan-2-yl)-1,2,4-triazole
• 化学式: C₉H₁₇N₃
• 分子量: 167.25
• InChiKey: WYENIXPXSPZRCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS
  申请人：Array BioPharma, Inc.

  公开号：US20160228441A1

  公开（公告）日：2016-08-11

  Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.

  用于合成用于治疗哺乳动物疼痛，癌症，炎症，神经退行性疾病或克鲁茨菌感染的化合物。
• Method of treatment using substituted imidazo[1,2b]pyridazine compounds
  申请人：Array BioPharma, Inc.

  公开号：US10011604B2

  公开（公告）日：2018-07-03

  Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification.

  用于治疗哺乳动物疼痛、癌症、炎症、神经退行性疾病、克氏扁虱感染和溶骨性疾病中的疾病或紊乱的方法，包括向所述哺乳动物施用治疗有效量的式 I 化合物 其中 R1、R2、R3、R4、X、Y 和 n 具有说明书中给出的含义。
• Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
  申请人：Array BioPharma Inc.

  公开号：US10774085B2

  公开（公告）日：2020-09-15

  Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.

  用于合成治疗哺乳动物疼痛、癌症、炎症、神经退行性疾病或克氏伤寒杆菌感染的化合物。
• US20140256546A1
  申请人：——

  公开号：US20140256546A1

  公开（公告）日：2014-09-11
• Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds
  申请人：Array BioPharma Inc.

  公开号：US20190169193A1

  公开（公告）日：2019-06-06

  Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I in which R 1 , R 2 , R 3 , R 4 , X, Y and n have the meanings given in the specification.